共 134 条
[1]
Torre LA(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108
[2]
Bray F(2017)EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer Eur Urol 71 630-642
[3]
Siegel RL(2008)The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis Clin Radiol 63 387-395
[4]
Ferlay J(2004)Overview of prostate-specific membrane antigen Rev Urol 6 S13-S18
[5]
Lortet-Tieulent J(2003)Prostate adenocarcinoma presenting with inguinal lymphadenopathy Urology 61 463-110
[6]
Jemal A(2012)The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis AJR Am J Roentgenol 199 103-85
[7]
Cornford P(1997)Prostate-specific membrane antigen expression in normal and malignant human tissues Clin Cancer Res 3 81-640
[8]
Bellmunt J(1998)Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases Urology 52 637-209
[9]
Bolla M(2015)The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Eur J Nucl Med Mol Imaging 42 197-697
[10]
Briers E(2012)68 Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging Bioconjug Chem 23 688-495